替格瑞洛治疗ST段抬高型心肌梗死的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (27 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect of Ticagrelor on acute ST-elevation myocardial infraction.Methods 120 patients with STEMI admitted to our hospital from January 2016 to January 2017 were performed primary PCI.According to the difference of treatment methods,the patients were divided into Ticagrelor group and Clopidogrel group.At the third month after procedure,the incidence of bleeding and major adverse cardiovascular events(MACE)between two groups were compared.Results In Ticagrelor group,the incidence of MACE was 3.3%,which was lower than that in the Clopidogrel group(8.3%),but no significant difference was observed between both groups(P＞0.05).Additionally,the incidence of bleeding,major without,minor was no significant difference was found between both groups(P＞0.05).Conclusion Ticagrelor has a tendency to reduce the incidence of MACE,without the increase of the bleeding incidence,in elderly patients with STEMI.

Key words： Ticagrelor Clopidogrel ST-elevation myocardial infarction Percutaneous coronary intervention

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Yang
	ZHENG Xiao-qun

Cite this article:

JIANG Yang,ZHENG Xiao-qun. The effect of Ticagrelor on acute ST-elevation myocardial infraction[J]. 中国当代医药, 2018, 25(9): 56-58.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I9/56

[1]	Zoheir N，Abd Elhamid S，Abulata N，et al.P2Y12 receptor gene polymorphism and antiplatelet of Clopidogrel in patients with coronary artery disease after coronary stenting[J].Blood Coagul Fibrinol，2013，24（5）：525-531.
[2]	Ibanez B，James S，Agewall S，et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J，2018，39（2）：119-177.
[3]	O'Gara PT，Kushner FG，Ascheim DD，et al.2013 ACCF ／AHA guideline for the management of ST elevation myocardial infarction[J].J Am Coll Cardiol，2013，61（4）：485-510.
[4]	Mehran R，Rao SV，Bhatt DL，et al.Standardized bleeding definitions for cardiovascular clinical trials：a consensus report from the Bleeding Academic Research Consortium[J].Circulation，2011，123（23）：2736-2747.
[5]	Chen C，Wei J，Al Badri A，et al.Coronary microvascular dysfunction-epidemiology，pathogenesis，prognosis，diagnosis，risk factors and therapy[J]Circ J，2016，81（1）：3-11.
[6]	Wallentin L，Beeker RC，Budaj A，et al.Ticagrelor versus Clopidogrel in patients with acute coronary syndromes[J].N Engl J Med，2009，361（11）：1045-1057.
[7]	Hamm CW，Bassand JP，Agewall S，et al.ESC Guidelines for the management oi acute eoronary syndromes in patients presenting without persistent ST-segment elevation：The Task Force for the management of acute coronary syndromes（ACS） in patients presenting without persistent ST-segment elevation of the European Socicty of Cardiolgy （ESC）[J].Eur Heart J，2011，32（23）：2999-3054.
[8]	OGara PT，Kushner FG，Aseheim DD，et a1.2013 ACCF/AHA guideline for the Management of ST-elevation myocardial infarction：a report of the American College of Cardiology Foundatinn/American Heart Association Task Force on practice guidelines[J].J Am Coll Cardiol，2013，61（4）：e78-e140.
[9]	Windecker S，Kolh P，Alfonso F，et a1.2014 ESC/EACTS Guidelines on myocardial revascularization：The Task Force on Myocardial Revascularization of the European Society of Cardiology （ESC） and the European Association for Cardio.Thoracic Surgery（EACTS） Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions （EAPCI）[J].Eur Heart J，2014，35（37）：254l-2619.
[10]	Amsterdam EA，Wenger NK，Brindis RG，et a1.2014 AHA/ACC guideline for the management of patients with non.ST-elevation acute coronary syndromes：a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J].Circulation，2014，130（25）：2354-2394.
[11]	Jeong YH，Smith SC Jr，Gurbel PA.Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med，2015，373（13）：1273-1274.
[12]	Ranehi F，Angiolillo DJ.Novel antiplatelet agents in acute coronary syndrome[J].Nat Rev Cardiol，2015，2（1）：30-47.
[13]	Steg PG，James S，Harrington RA，et al.Ticagrelor versus Clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention：A Platelet Inhibition and Patient Outcomes（PLATO） trial subgroup analysis[J].Circulation，2010，122（21）：2131-2141.
[14]	Montalescot G，van′t Hof AW，Lapostolle F，et al.Prehospital ticagrelor in ST segment elevation myocardial infarction[J].N Engl J Med，2014，371（11）：1016-1027.
[15]	Gurbel PA，Bliden KP，Butler K，et al.Response to ticagrelor in Clopidogrel nonresponders and responders and effect of switching therapies：the respond study[J].Circulation，2010，121（10）：1188-1199.